Adiso Therapeutics

Advancing Novel Therapies for Inflammatory Diseases

[Adiso Therapeutics @AdisoTx]

@ScienceofPD "GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA understanding for a biotherapeutic! [LPA3 agonism]@UCC @Pharmabiotic #Parkinsons #MultipleSclerosis

[Adiso Therapeutics @AdisoTx]

"GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA understanding for a biotherapeutic! [LPA3 agonism] #Parkinsons #MultipleSclerosis #Neuroscience

[いっちー@バーチャル精神科医 @ichiipsy]

発酵食品やヨーグルトに含まれる乳酸菌がストレスへの抵抗力と抑うつ・不安予防に役立つことを示唆する論文。バージニア大学の研究によれば、乳酸菌は免疫機能を調整して気分に影響を及ぼし、抑うつや不安などのメンタルヘルスの予防・治療に役立つ可能性が示された。
(Brain Behavior and Immunity)

[Adiso Therapeutics @AdisoTx]

Team @AdisoTx thrilled with latest ADS024 publication - an oral single strain live biotherapeutic (SS-LBP) This research highlights the potential role of ADS024 for neuroinflammatory conditions #MS #Parkinson #FA #Huntingtons #Patientsfirst #neuroinflammaiton @UCC #GCPR #ALS

[UCC Innovation @uccinnovation]

Good luck to @UCC spinout @AdisoTx at the @KTIconnect Awards tonight. We sat down with Professor Paul Ross, one of the founders of @AdisoTx, to discuss the history of @AdisoTx & its achievement of being shortlisted for the commercialisation award – https://t.co/JNAquwbapm

[Sally Cudmore @Sscudz]

@KTIconnect awards have just started. Good luck to all those short listed, especially @UCC and @Pharmabiotic spin- out company @AdisoTx shortlisted for the Commercialisation Award #ktiawards

[Prof. Barry O'Sullivan, MRIA @BarryOSullivan]

@uccinnovation @KTIconnect @AdisoTx @KathrionaDev Great to see Michéal and Kathriona at this important event. We’ll done everyone.

[The Science of Parkinson's @ScienceofPD]

Interesting: @parasmin et al report inhibition of indoleamine-2,3-dioxygenase 1 (IDO1) & production of kynurenine rescues hippocampal synaptic plasticity & memory function in models of amyloid & tau pathology (via astrocytic metabolic support of neurons)
https://t.co/DbZGE9OUdB

[The Science of Parkinson's @ScienceofPD]

Interesting: Adiso Therapeutics @AdisoTx researchers present a LPA3 agonist-producing Bacillus velezensis (called ADS024) whose anti-neuroinflammatory properties corrects multiple models of #Parkinsons (& #MultipleSclerosis, #Huntingtonsdisease, #ALS, etc)
https://t.co/fhtDt866GD

[Adiso Therapeutics @AdisoTx]

Adiso is developing ADS051 to provide patients a new treatment opportunity. We believe this mission is fulfilled by keeping #patientsfirst. Listen to our recent podcast with @rahulc of the @Biotech2050Pod https://t.co/WIiCNpn80d
#Leadership
#IBD
#ulcerativecolitis

[Biotech2050 Podcast @Biotech2050Pod]

Join host @rahulc in the latest episode of the Biotech2050 podcast with Scott Megaffin, CEO of @AdisoTx, as they discuss differentiation and collaboration in the biotech industry

Listen to the episode: https://t.co/eXjmOtTLP1

[Adiso Therapeutics @AdisoTx]

We look forward to participating in the virtual @CG_Driven Inflammatory Bowel Disease Symposium this Wednesday. Tune in to the “Emerging Novel Targets in IBD” panel to hear Adiso CEO Scott Megaffin discuss our highly differentiated approach to treating #inflammatorydiseases.

[Adiso Therapeutics @AdisoTx]

From the Adiso team to you, have a safe and happy #holidayseason. As we approach the new year, we’d like to reflect on our 2023 milestones and express gratitude to all who have contributed to our achievements. May your time with friends and family be filled with joy.

[Adiso Therapeutics @AdisoTx]

Connect with Adiso at #BiotechShowcase in San Francisco next month! Get in touch with us directly at [email protected] or through the partnering platform to schedule a meeting: https://t.co/dfa6qfVTHo

#Inflammatorydisease
#Ulcerativecolitis
#Biotech

[Adiso Therapeutics @AdisoTx]

Adiso is pleased to announce a Precision Immunology collaboration with @GeneoscopyCo investigating therapeutic options for patients with #IBD. Employing #RNA biomarker technology developed by Geneoscopy in conjunction with ADS051. Learn more: https://t.co/BTmUTPd2gE

[Adiso Therapeutics @AdisoTx]

Today kicks off Crohn’s & Colitis Awareness Week. Year-round, we are dedicated to advancing research and development of novel therapies for patients with #ulcerativecolitis and other #inflammatorydiseases. Read about our progress: https://t.co/BPBJnJeY9H #IBDVisible

[Adiso Therapeutics @AdisoTx]

We wish a happy Thanksgiving to all, with gratitude for the courageous patients who participated in Adiso clinical trials, as well as our advisors and partners for their guidance and unwavering support. From our team to you, have a healthy and happy #Thanksgiving! #PatientsFirst

[Adiso Therapeutics @AdisoTx]

We’re excited to participate in the @WellsFargo 2023 Virtual Private Biotech Symposium, fresh off the heels of our positive topline data announcement from our Phase 1b study of ADS051! Connect with us to learn about our great progress.

#ulcerativecolitis
#inflammatorydisease

[Adiso Therapeutics @AdisoTx]

Our team was overjoyed to unveil positive topline data from our Phase 1b MAD study highlighting the potential of ADS051 as a safe and effective therapy for #ulcerativecolitis. We’re excited to advance ADS051 in a Phase 2 trial. Learn more: https://t.co/kyD4BHBUil

[Adiso Therapeutics @AdisoTx]

It’s with great pleasure that we announce positive topline data presented at #ACG2023 from our Phase 1b MAD study of ADS051, a first-in-class, oral, gut-restricted, small molecule neutrophil modulator for #ulcerativecolitis! Read the release: https://t.co/kyD4BHBUil

[Adiso Therapeutics @AdisoTx]

We’re delighted to welcome Robert Lisicki, an accomplished #biopharma industry executive, to our Board of Directors! Rob’s expertise will be an integral resource as we advance our neutrophil modulator, ADS051, to Phase 2 for #IBD. Learn more: https://t.co/5ZM6hs56Nn